Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Dermatomyositis and Polymyositis
NCT00033891Phase 2Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Apr 2002
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dermatomyositis (DM) and polymyositis (PM) comparing Infliximab with Placebo (2 arms). Primary endpoint: Manual Muscle Testing Score at 16 weeks. Started Apr 2002; status: completed.
02
Drugs
infliximab
03
Conditions
dermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on NCT00033891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033891.